scholarly journals Chemotherapy followed by low dose radiotherapy in childhood Hodgkin's disease: retrospective analysis of results and prognostic factors

2006 ◽  
Vol 1 (1) ◽  
Author(s):  
Gustavo A Viani ◽  
Marcus S Castilho ◽  
Paulo E Novaes ◽  
Celia G Antonelli ◽  
Robson Ferrigno ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Retrospective Analysis ◽  
Hodgkin's Disease ◽  
Low Dose ◽  
Hodgkin’S Disease ◽  
Low Dose Radiotherapy ◽  
Analysis Of Results

Chemotherapy followed by low dose radiotherapy in childhood Hodgkin’s disease. Retrospective analysis of results and prognostic factors

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 9039-9039
Author(s):  
G. Viani ◽  
P. Novaes ◽  
J. Salvajoli ◽  
R. Ferrigno ◽  
C. Pellizzon ◽  
...  
Keyword(s):  
Platelet Count ◽  
Prognostic Factors ◽  
Hodgkin's Disease ◽  
Low Dose ◽  
Hodgkin’S Disease ◽  
Clinical Stage ◽  
Young Patients ◽  
Symptom Duration ◽  
Female Ratio ◽  
Low Dose Radiotherapy

9039 Background: To report on treatment results and prognostic factors of young patients with Hodgkin’s disease treated with chemotherapy (CT) followed by low dose radiotherapy (RT). Methods: This retrospective series analysed 166 patients under 18 years old, treated from January 1985 to December 2003. Median age was 10 years (range 2–18). The male to female ratio was 2,3:1. Adenomegalia was the most frequent complaint (68%), and the time of symptom duration was smaller than 6 months in 55% of the patients. In histological analysis Nodular Sclerosis was the most prevalent type (43%) followed by Mixed Celularity (41%). The disease was restricted to two nodal group ( stage II) in 60% and to adjacent groups in 55% (stage III). The most frequent site of metastasis ware the bone marrow (38%) and lungs (42%). Standard treatment consisted of chemotherapy (drug combination varied according to treatment protocols vigent). Radiotherapy consisted of 21 Gy dose in 17 fractions in most part of patients (90.2%), delivered to involved field or mantle field. 13,86% patients did not receive RT. Results: The OS and EFS in 10 years were 88.6% and 82.4%.Survival according to clinical stage as 94.4%, 94.25%, 90.6% and 71.5% for stages I to IV (p=0.0215). The OS in 90.5% of patients who received RT and in 75.6% of patients who did not (p=0.001). Multivariate analysis showed presence of B symptoms and low platelet count to be associated with a worse prognosis. Conclusions: This study shows that combining chemotherapy and low dose RT is an effective treatment for HL in childhood, providing high rates of cure and disease control (88.6% in 10 years), and that so far it is not possible to abdicar RT. And yet, attention to platelet count should be payed in order to improve survival. Also, B symptom presenting children may be involved in more aggressive protocols so survival can be improved. As the disease is highly curable, any data of long term follow-up should be presented in order to better direct therapy, improving outcome and lowering side effects. No significant financial relationships to disclose.

scholarly journals Late cardiac effects after treatment for childhood Hodgkin's disease with chemotherapy and low-dose radiotherapy.

1995 ◽  
Vol 71 (833) ◽  
pp. 164-167 ◽  
Author(s):  
I. Ilhan ◽  
F. Sarialioglu ◽  
N. Ozbarlas ◽  
M. Buyukpamukcu ◽  
C. Akyuz ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Low Dose ◽  
Hodgkin’S Disease ◽  
Cardiac Effects ◽  
Low Dose Radiotherapy

Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.

1991 ◽  
Vol 9 (9) ◽  
pp. 1591-1598 ◽  
Author(s):  
M A Weiner ◽  
B G Leventhal ◽  
R Marcus ◽  
M Brecher ◽  
J Ternberg ◽  
...  
Keyword(s):  
Pediatric Oncology ◽  
Hodgkin's Disease ◽  
Low Dose ◽  
Residual Disease ◽  
Hodgkin’S Disease ◽  
Acute Myelocytic Leukemia ◽  
Advanced Stage ◽  
Oncology Group ◽  
Low Dose Radiotherapy ◽  
Pediatric Oncology Group

Sixty-two patients with advanced-stage Hodgkin's disease and a median age of 12 years (range, 3 to 22 years) were treated with four cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) alternating with four cycles of doxorubicin, vinblastine, bleomycin, and dacarbazine (ABVD) followed by low-dose radiotherapy (RT). We determined the feasibility, immediate safety, and rapidity of response of patients to this regimen, as well as the relationship between prognostic factors and the rate of complete remission (CR), event-free survival (EFS), and overall survival. Therapy was well tolerated, and the major toxicity was hematopoietic. At the end of chemotherapy, 54 of 62 patients (87%) were in CR by clinical restaging, with a biopsy of residual disease where necessary. The actuarial 3-year EFS is 77% (SE, 11%), with a median follow-up of 35 months, and the survival is 91% (SE, 7%). With respect to EFS, female patients and those with stage II or III disease fared statistically better than males and patients with stage IV disease, respectively. Six patients have died: three of progressive Hodgkin's disease, one of secondary acute myelocytic leukemia (AML), one of secondary non-Hodgkin's lymphoma (NHL), and one of overwhelming bacterial sepsis. The Pediatric Oncology Group (POG) is currently engaged in a randomized study of these eight cycles of chemotherapy with and without RT to assess the role of RT in achieving comparable results.

Hodgkin'S Disease in Northern Sweden 1971-1981 Ii. A Retrospective Analysis of Prognostic Factors

1991 ◽  
Vol 30 (5) ◽  
pp. 597-601 ◽  
Author(s):  
B. Norberg ◽  
U. Dige ◽  
G. Roos ◽  
H. Johansson ◽  
P. Lenner
Keyword(s):  
Prognostic Factors ◽  
Retrospective Analysis ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Northern Sweden

Breast cancer after hodgkin's disease: Retrospective analysis of 30 cases

2020 ◽  
Vol 46 (12) ◽  
pp. e9
Author(s):  
S. Michieletto ◽  
F. Milardi ◽  
M. Cagol ◽  
R. Grigoletto ◽  
L. Rigato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Analysis ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease

Localized Childhood Hodgkin’s Disease: Response-Adapted Chemotherapy With Etoposide, Bleomycin, Vinblastine, and Prednisone Before Low-Dose Radiation Therapy—Results of the French Society of Pediatric Oncology Study MDH90

2000 ◽  
Vol 18 (7) ◽  
pp. 1500-1507 ◽  
Author(s):  
J. Landman-Parker ◽  
H. Pacquement ◽  
T. Leblanc ◽  
J.L. Habrand ◽  
M.J. Terrier-Lacombe ◽  
...  
Keyword(s):  
Survival Rate ◽  
Pediatric Oncology ◽  
Hodgkin's Disease ◽  
Low Dose ◽  
Hodgkin’S Disease ◽  
Alkylating Agents ◽  
Poor Responders ◽  
Event Free Survival ◽  
French Society ◽  
Free Survival

PURPOSE: The French Society of Pediatric Oncology MDH82 study demonstrated the effectiveness of 20 Gy irradiation of involved fields after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or mechlorethamine, vincristine, procarbazine, and prednisone/ABVD chemotherapy in children with localized Hodgkin’s disease (HD). The response to primary chemotherapy was the only predictor of survival. To reduce long-term treatment complications without compromising efficacy, the MDH90 study was based on a new chemotherapy regimen devoid of both alkylating agents and anthracycline, followed by 20 Gy of radiotherapy (RT) for good responders. PATIENTS AND METHODS: From January 1990 to July 1996, 202 children were enrolled from 30 institutions. Good responders to four cycles of vinblastine, bleomycin, etoposide (VP16), and prednisone (VBVP) were given 20 Gy of RT and no further therapy. Poor responders were given vincristine, procarbazine, prednisone, and doxorubicin. After a second evaluation, good responders were given 20 Gy of RT, and poor responders were given 40 Gy of RT. RESULTS: One hundred seventy-one patients (85%) were good responders to VBVP, 27 (15%) were poor responders, and four did not respond. With a median follow-up of 74 months (range, 25 to 117 months), the 5-year overall survival rate (mean ± SD) is 97.5% ± 2.1%, and the event-free survival rate (mean ± SD) is 91.1% ± 1.8%. Significant predictors of worse event-free survival in multivariate analysis were hemoglobin < 10.5 g/L, “b” biologic class, and nodular sclerosis. CONCLUSION: These results suggest that most children with clinical stage I and II HD can be treated with chemotherapy devoid of alkylating agents and anthracycline, followed by low-dose RT.

Sign in / Sign up

Export Citation Format

Share Document